Showing 8511-8520 of 21414 results for "".
Understanding Dapagliflozin: Examining Its Use in Chronic Kidney Disease
https://reachmd.com/programs/diabetes-discourse/understanding-dapagliflozin-examining-its-use-in-chronic-kidney-disease/12251/Can a treatment option used for type 2 diabetes help those with chronic kidney disease?Interventions Targeting Impaired Glucose Tolerance
https://reachmd.com/programs/diabetes-discourse/interventions-targeting-impaired-glucose-tolerance/5010/The ACT NOW study examined whether treatment of impaired glucose tolerance in pre-diabetic patients with pioglitazone could prevent or delay the development of type 2 diabetes. Join host Dr. Steven Edelman and his guest, endocrinologist and professor of medicine at the University of California San DChoosing Between Insulin and Incretin Therapies
https://reachmd.com/programs/diabetes-discourse/choosing-between-insulin-and-incretin-therapies/6170/When should healthcare professionals treating patients with type 2 diabetes consider using insulin or incretin treatment or both? Join host Dr. Steven Edelman and his guest, president-elect of the American Diabetes Association and professor of medicine at Tulane University, Dr. Vivian Fonseca, as thInsulin-Like Effects on Exercising Muscles
https://reachmd.com/programs/focus-on-sports-medicine/insulin-like-effects-on-exercising-muscles/3899/Dr. Laurie Goodyear, a senior investigator and head of the section on metabolism at the Joslin Diabetes Center in Boston, discusses with host Dr. Larry Kaskel how exercise impedes the development of type 2 diabetes. Tune in to hear the implications of Dr. Goodyear's research on exercise and how it wIncretin-Based Advances in Obesity and T2D Care
https://reachmd.com/programs/diabetes-discourse/incretin-advances-obesity/57025/For patients with obesity and type 2 diabetes (T2D), emerging incretin-based therapies that target multiple metabolic pathways are producing meaningful weight-loss outcomes. To learn more about these care strategies, tune in as Dr. Javier Morales shares key updates from the 2026 American Diabetes AsNewt Gingrich: Improving Care for Diabetics
https://reachmd.com/programs/clinicians-roundtable/newt-gingrich-improving-care-for-diabetics/1338/Perhaps best known for his Contract with America and the subsequent Republican control of the House of Representatives for 12 years, many physicians do not know how strong a healthcare advocate former Speaker of the House Newt Gingrinch has become, or the tranformations in health policy he began pioOptimizing Anti-VEGF Selection in Diabetic Macular Edema
https://reachmd.com/programs/eye-on-ocular-health/optimizing-anti-vegf-selection-in-diabetic-macular-edema/60933/Choosing the right anti-VEGF therapy is an important part of optimizing long-term outcomes for patients with diabetic macular edema (DME). Discover how to select the right therapy, incorporate longer-acting agents into practice, and balance durability and long-term disease management with Dr. MichaeAssessing Glucose Control & Reducing Cardiovascular Risk in Patients with Diabetes
https://reachmd.com/programs/diabetes-discourse/assessing-glucose-control-reducing-cardiovascular-risk-in-patients-with-diabetes/12769/Could glucose control mitigate cardiovascular risk in diabetic patients?What’s Happening in Hypoglycemia?
https://reachmd.com/programs/diabetes-discourse/whats-happening-in-hypoglycemia/4692/The frequency of hypoglycemic events for both type 1 and type 2 diabetics increases due to tight blood glucose control and more intensive treatment schedules. The disease differs significantly between type 1 and type 2 in the body’s defense mechanism of decreasing insulin concentration. Join host DrA New Health Plan to Eliminate Diabetes Patients’ Out-of-Pocket Costs
https://reachmd.com/programs/the-drug-report/a-new-health-plan-to-eliminate-diabetes-patients-out-of-pocket-costs/11286/CVS Health recently announced a new plan to eliminate out-of-pocket costs associated with diabetes prescription medicines. Here are the details.